高维鹏 brings an unusual combination of legal, banking, and investment experience to healthcare venture capital, having worked as a practicing lawyer for six years serving major financial institutions, then as assistant general manager at Commonwealth Bank of Australia's China division, before transitioning to equity investment management at BioVenture where he focuses on medical and some advanced manufacturing/energy projects. He has publicly advocated for allowing unprofitable companies to list on China's STAR Market, arguing that high R&D spending is a normal and sustainable path for innovation rather than simply a risk factor, and specifically highlights autism rehabilitation services as a potentially overlooked sector where international firms like KKR are already increasing their investments.